Guggenheim Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $61.39 +1.35%
Rating Summary:
11 Buy, 23 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
11 Buy, 23 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Guggenheim analyst Seamus Fernandez upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Neutral to Buy with a price target of $62.00.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $51.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Churchill Downs (CHDN) PT Lowered to $131 at Stifel, Stays on Stifel Select List
- HSBC Upgrades FedEx (FDX) to Buy
- Canaccord on Sandisk (SNDK): 'The star was the data center business'
Create E-mail Alert Related Categories
UpgradesRelated Entities
Maynard Um, Guggenheim, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
